Increased expression of CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected CAPD

A Brauner1, B Hylander, S H Jacobson

  • 1Department of Clinical Microbiology and MTC, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.

Inflammation
|February 8, 2002
PubMed

Insights

Uremia and dialysis treatments reduce lymphocyte counts. However, lymphocytes in peritoneal dialysis fluid show signs of activation, potentially explaining infection susceptibility in patients undergoing dialysis.

Area of Science:

  • Immunology
  • Nephrology
  • Clinical Medicine

Background:

  • Uremia and dialysis treatments can impact immune function.
  • Understanding lymphocyte alterations is crucial for managing infections in kidney disease patients.

Purpose of the Study:

  • To evaluate the impact of uremia, peritoneal dialysis (PD), and hemodialysis (HD) on lymphocyte characteristics.
  • To compare lymphocyte profiles in peripheral blood and peritoneal dialysate.

Main Methods:

  • Flow cytometry was used to analyze CD4, CD8, CD25, and HLA-DR markers on lymphocytes.
  • Samples were obtained from peripheral blood of uremic, HD, and CAPD patients, and from CAPD dialysate.

Main Results:

  • Reduced lymphocyte counts were observed in the peripheral blood of uremic, HD, and CAPD patients compared to controls.
  • Lymphocytes in peritoneal dialysate showed a higher relative distribution and increased activation markers (CD25, HLA-DR) compared to peripheral blood.
  • Absolute CD4 counts were lower in the peripheral blood of all patient groups.

Conclusions:

  • Dialysis treatments and uremia lead to decreased peripheral lymphocyte counts.
  • Selective lymphocyte activation occurs within the peritoneal dialysate, suggesting localized immune responses.
  • Altered lymphocyte function may contribute to increased infection risk in dialysis patients.